Crescent Pharma recalls Ramipril 2.5mg due to packaging error
Crescent Pharma Limited is recalling Ramipril 2.5mg capsules due to a packaging error that may lead to patients receiving the incorrect dosage.
Company
Crescent Pharma Limited
Asset
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The recall of Ramipril 2.5mg capsules due to a packaging error poses significant risks to patient safety and could lead to reputational damage for Crescent Pharma. This situation necessitates a thorough investigation to understand the potential implications for regulatory compliance and market positioning.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor for reports of adverse events related to the incorrect dosage and any regulatory responses.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.